<DOC>
	<DOCNO>NCT02951364</DOCNO>
	<brief_summary>The primary objective post-marketing surveillance study collect ass data relate safety effectiveness HarvoniÂ® ( ledipasvir/sofosbuvir ( LDV/SOF ) ) treatment regimen , per approve Korea prescribe information Harvoni , routine clinical practice Korea report result Ministry Food Drug Safety ( MFDS ) . Patients treat part routine practice Korean healthcare center accredit physician .</brief_summary>
	<brief_title>Harvoni Patients With Chronic Hepatitis C Virus ( HCV ) Infection Korea</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ledipasvir , sofosbuvir drug combination</mesh_term>
	<criteria>Key Patients age 18 year old live Korea Patients chronic HCV infection eligible treatment Harvoni indicate approve prescribe information Harvoni Patients inform pertinent aspect study voluntarily sign informed consent form Key Patients treat Harvoni outside approve prescribe information Korea Patients contraindication Harvoni Patients contraindication ribavirin Pregnant breastfeed woman Patients previously administer Harvoni Patients participate concurrent HCV clinical trial Patients plan leave country study period Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>observational</keyword>
</DOC>